The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

A leader in therapeutic antibodies, ImClone Systems (also called "the company") is committed to advancing oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. Founded in 1984, ImClone has a rich culture of discovery and deep expertise in oncology. The company has utilized the many advances made in the fields of molecular biology, oncology, genomics, and antibody engineering to build a novel pipeline of product candidates designed to address specific genetic mechanisms involved in cancer growth and development. Beyond its blockbuster marketed product ERBITUX®, ImClone has several additional investigational monoclonal antibodies in various stages of clinical development. Following its acquisition by Eli Lilly and Company in 2008, ImClone Systems is accelerating its antibody pipeline development by leveraging Lilly's global capabilities. ImClone's pipeline has several molecules in mid- to late-stage clinical development targeting virtually all major solid tumor types. Additionally, ImClone plans to advance several additional targets from its research programs into clinical development over the coming years. ImClone's research and clinical development capabilities are augmented by its expertise in the scale-up and manufacturing of biologics. The company's state-of-the-art FDA-approved manufacturing facilities in Branchburg, New Jersey, provide it with one of the largest biologic manufacturing capacities in the world. ImClone's Branchburg campus also houses it clinical development and administration operations. The company's research headquarters are based in New York City and it has international operations in Europe.

COR Therapeutics is engaged in the discovery, development, and marketing of novel therapeutic products for treating and preventing acute and chronic cardiovascular diseases. The company’s product portfolio includes Integrilin Injection which is used to treat individuals with cardiovascular diseases. COR Therapeutics also has several product development programs underway to address unmet clinical needs in the management of patients suffering from disorders such as unstable angina, coronary angioplasty, acute myocardial infarction, stroke, and deep vein thrombosis. COR Therapeutics was founded by Lee Douglas and Lewis T. ""Rusty"" Williams in San Francisco, California.

Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA.

Azienda Ospedaliero-Universitaria Careggi is a private company headquartered in Florence, Italy. The firm operates as a hospital.

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

Qingdao Enpu Biotechnology Co., Ltd., established on 2020-02-07, Business scope includesIkind,Class II,IIIproduction of medical devices,Sales,Cosmetic production,Sales(except dangerous goods),Disinfection supplies sales,Production of labor insurance products,Sales(dangerous goods,except chemical products),General merchandise sales,biotechnology research,technology development,Import and export of the above goods and technologies(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval)(The above projects are engaged in business activities in accordance with the license issued by the competent industry department).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Juwei Cell (Xiamen) Medical Technology Co., Ltd., established on 2017-12-13, Business scope includes medical research and experimental development;Other unspecified technology promotion and application service industries;Natural science research and experimental development;Engineering and Technology Research and Experimental Development;Social Humanities Research;Other unlisted professional and technical service industries(Not subject to permit approval);Medical Information Consulting Service(Does not include drug information services,Disease diagnosis and treatment and other items subject to permit approval);Health food wholesale;Other unlisted professional consulting services(Items not subject to permit approval);Health Food Retail;Business Management Consulting;Business Consulting;Biotechnology Extension Services;Data Processing and Storage Services;Energy-saving technology promotion service;Other technical promotion services;Information system integration service;Other unspecified information technology service industry(Items not subject to permit approval);Information Technology Consulting Services;Wholesale of other chemical products(Free of hazardous and monitored chemicals);Wholesale of cosmetics and hygiene products;Other unspecified manufacturing industries(Items not subject to permit approval);Retailing of cosmetics and hygiene products;advertising design,make,acting,release;internet sales;market management;Other Trade Brokers and Agents;trade agent;Other unspecified wholesale business(Does not include business items subject to permit approval);Wholesale of other unlisted prepackaged foods(Does not contain refrigerated frozen food);Other unspecified retail trade(Items not subject to permit approval);Retail sale of other unspecified prepackaged food(Does not contain refrigerated frozen food);pastry,Candy and sugar pre-packaged food wholesale(Does not contain refrigerated frozen food);pastry,Bakery Prepackaged Food Retail(Does not contain refrigerated frozen food);liquor,Beverage and tea prepackaged food wholesale(Does not contain refrigerated frozen food);liquor,Beverage and tea prepackaged food retail(Does not contain refrigerated frozen food).

Guangzhou Institutes of Biomedicine and Health (GIBH)，(simplified Chinese: 中国科学院广州生物医药与健康研究院; traditional Chinese: 中國科學院廣州生物醫藥與健康研究院; pinyin: Zhōngguó Kēxué yuan guangzhou sheng wu yi yao yu jian kang yan jiu yuan) affiliated with the Chinese Academy of Sciences, is a government-sponsored scientific research institution with independent legal jurisdiction. GIBH was established by the Chinese Academy of Sciences, Guangdong Provincial Government and Guangzhou Municipal Government. The managerial mechanism of GIBH is the responsibility of Director-General, under the authority of the board of trustees.

Shanghai Ruizhi Medical Technology Service Co., Ltd., established on 2015-11-30, The scope of business includes engaging in pharmaceutical chemical technology,Technology development in the field of biotechnology,technical consulting,Technical Services,technology transfer,Business Consulting,account Serive,Etiquette service,Enterprise Marketing Planning,Corporate Image Planning,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Changzhou Adam Biotechnology Co., Ltd., established on 2010-09-08, Business scope includes biomedicine,chemistry medicine,R&D and technical services of natural medicines;disinfection products,R&D and sales of cosmetics;Food research and development and sales(limit<food business license>Approved scope).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Sales of Class I Medical Devices;Sales of Class II Medical Devices;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Kaihui Ruizhi Biotechnology (Shanghai) Co., Ltd., established on 2015-07-20, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development(remove human stem cells,Development and application of genetic diagnosis and treatment technology);Import and export;Technology Import and Export;Specialty Chemicals Sales(Free of Hazardous Chemicals);Chemical product sales(No licensed chemical products);Synthetic Materials Sales;Sales of packaging materials and products;Sales of plastic products;Food Additive Sales;General Cargo Warehousing Services(Does not contain hazardous chemicals and other items that require approval);Low temperature storage(Does not contain hazardous chemicals and other items that require approval).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Beech Mountain Resort, Inc. is an American private company. The firm operates ski resorts.

In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. At Takeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer. They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.

Harbin One Plus One Regenerative Medicine Technology Co., Ltd., established on 2010-04-23, Business scope includes licensed projects:accommodation service;Catering Services.General project:Medical Research and Experimental Development;Human stem cell technology development and application;Development of Human Gene Diagnosis and Therapy Technology;R&D and application of cell technology;Park Management Services;Entrepreneurial Space Services;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology intermediary service;Conference and Exhibition Services;business management;Financial Advisory;translation service;Business agency service;Information Consulting Service(Not including licensing information consulting services);Project planning and public relations services;marketing planning;business training(Does not include education and training,Vocational skills training and other licensed training);property management;Horticultural Products Planting.

Xiamen Zhongling Precision Medicine Industry Development Co., Ltd., established on 2015-04-20, Business scope includes medical research and experimental development;outpatient department(Place);Centers for Disease Control and Prevention;Natural science research and experimental development;Biotechnology Extension Services;Other unspecified technology promotion and application service industries;Investment Advisory(law,Unless otherwise specified by law);Business Consulting;Business Management Consulting;Technology intermediary service;Investment Management Consulting(law,Unless otherwise specified by law);textile,Wholesale of knitted goods and raw materials;Retailing of Textiles and Knitwear;Wholesale of cosmetics and hygiene products;Retailing of cosmetics and hygiene products;Other daily necessities retail;Wholesale of other mechanical equipment and electronic products;Other Electronics Retail.

Chongqing Kerun Biomedical R&D Co., Ltd. was established in 1997, formerly known as Chongqing Rainwater Group Duotai Biomedical Research Institute, focusing on the research and development of recombinant protein drugs. After nearly two decades of development, the company has established a mature yeast expression technology platform and E. coli expression technology platform, and is currently actively building a mammalian cell expression platform. A drug development system with specifications from options, upstream construction, protein expression, process development, quality control, and registration declarations.

Shanghai Laifu Medical Technology Co., Ltd., established on 2016-11-02, The scope of business includes engaging in medical,biology,Technology development in the field of medical science and technology,technical consulting,Technical Services,technology transfer,Culture and preparation of immune cells and various stem cells,Freeze,Quality inspection and drug development,Health Management Consulting Services,Business Management Consulting,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.